You might also read
Articles linked to this work by shared authors, journal, and citation graph.
This study examines how different strains of mice and rats respond to high-fat and high-cholesterol diets, specifically looking at changes in blood lipid levels and the effectiveness of common cholesterol-lowering medications.
Area of Science:
Background:
Researchers often struggle to select appropriate animal models for studying lipid metabolism due to significant physiological variations across species. Prior research has shown that dietary interventions can alter plasma lipid profiles, yet the consistency of these responses remains unclear. No prior work had resolved how specific genetic backgrounds influence the development of elevated blood fats. That uncertainty drove the need for a comparative analysis of common laboratory rodents. It was already known that high-cholesterol diets typically trigger metabolic shifts in mammals. This gap motivated an examination of how diverse strains react to standardized dietary challenges. Scientists require reliable models to evaluate therapeutic agents effectively. This investigation addresses the variability inherent in rodent-based lipid research.
Purpose Of The Study:
The aim of this study is to characterize the differences in experimental hyperlipidemia across various mouse strains and rat models. Researchers sought to determine how genetic background influences metabolic responses to dietary lipid challenges. The investigation addresses the lack of standardized models for testing cholesterol-lowering interventions. This uncertainty drove the need to compare lipid profiles in ddY, C57BL, BALB, and ICR mice against Wistar rats. The team examined whether dietary fat and cholesterol induce uniform changes in blood lipid concentrations. Scientists also evaluated the efficacy of common hypolipidemic agents across these diverse animal groups. This work clarifies the limitations of using specific rodents for metabolic research. The study provides a foundation for selecting appropriate models in future cardiovascular and metabolic investigations.
The researchers propose that rats exhibit increased triglyceride levels following dietary intervention, whereas mice consistently show a decrease in this specific lipid marker across all tested strains.
The study utilized a high-cholesterol diet administered over a two-week period or a high-fat emulsion provided for one week to induce lipid imbalances.
The authors state that clofibrate administration successfully lowered total cholesterol and triglycerides while elevating high-density lipoprotein cholesterol in rats, but failed to produce similar results in most mouse strains.
The investigators measured plasma levels of total cholesterol, triglycerides, and high-density lipoprotein cholesterol to assess the metabolic impact of the dietary and pharmacological interventions.
Main Methods:
Review approach involved a comparative assessment of lipid profiles across four distinct mouse strains and Wistar rats. Investigators utilized standardized dietary challenges to induce metabolic alterations in all animal groups. The team administered high-cholesterol diets for fourteen days to observe long-term lipid changes. Alternatively, researchers employed high-fat emulsions over seven days to trigger rapid lipid accumulation. The study evaluated the pharmacological impact of clofibrate and nicotinic acid at daily doses of 100 milligrams per kilogram. Scientists also examined the therapeutic potential of gemfibrozil, LK-903, and pirozadil within these models. The experimental design focused on quantifying plasma concentrations of cholesterol and triglyceride fractions. This systematic approach allowed for the direct comparison of metabolic responses between different rodent species.
Main Results:
Key findings from the literature indicate that total cholesterol levels rose in all rodents following dietary intervention, although the magnitude of this increase was lower in mice than in rats. Plasma triglyceride concentrations increased in rats but unexpectedly declined in all mouse strains tested. High-density lipoprotein cholesterol levels decreased in most animals, with the notable exception of BALB mice. Relative liver weight consistently increased across all rodent groups when fed a high-cholesterol diet. Clofibrate treatment effectively reduced total cholesterol and triglycerides while raising high-density lipoprotein in rats. In contrast, clofibrate only lowered total cholesterol in ICR mice fed the high-cholesterol diet. The study further explored the hypolipidemic potential of gemfibrozil, LK-903, and pirozadil in both rats and ICR mice. These results demonstrate that metabolic responses to both diet and medication are highly dependent on the specific animal model used.
Conclusions:
The authors conclude that metabolic responses to dietary challenges vary significantly between mice and rats. Synthesis and implications suggest that rodent strain selection dictates the observed efficacy of lipid-lowering drugs. Researchers propose that rats exhibit distinct triglyceride patterns compared to the mouse strains tested. The data indicate that clofibrate displays limited hypolipidemic activity in mice compared to its robust effects in rats. These findings imply that therapeutic screening requires careful consideration of species-specific physiological traits. The study highlights that BALB mice maintain unique high-density lipoprotein profiles under dietary stress. Investigators suggest that future metabolic studies must account for these inherent inter-species differences. The evidence supports the necessity of validating drug responses across multiple animal models before clinical translation.
The researchers report that relative liver weight increased in both species following the high-cholesterol diet, indicating a shared physiological response to the dietary challenge despite other metabolic differences.
The authors suggest that the limited hypolipidemic effects observed in mice highlight the importance of species-specific screening when testing novel compounds like gemfibrozil or pirozadil.